Keywords: Curis, Genentech, Roche, GDC-0917, CUDC-427, Ph I

Curis in-licenses cancer candidate from Genentech

Article | 30 November 2012

Print This

US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss pharma major Roche ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in